Form 4: Oncology Institute Director Forfeits Shares After Performance Targets Missed

A director at Oncology Institute, Mark L. Pacala, forfeited a total of 50,620 unvested restricted shares due to the company's stock price failing to meet specific earn-out targets.

Summary

• Mark L. Pacala, a director at Oncology Institute, forfeited 20,248 shares of common stock due to the company's stock price not reaching $12.50 for 20 days within a 30-day period.
• An additional 30,372 shares were forfeited because the stock price did not reach $15.00 for 20 days within a 30-day period.
• These forfeitures are related to earn-out targets set after the closing of the Business Combination on November 12, 2021.
• The earn-out targets were based on the company's stock price performance over a three-year period, subject to continued employment.

Sentiment

Score: 3

Explanation: The document indicates a failure to meet performance targets, leading to share forfeitures, which is a negative signal for investors.

Negatives

• The forfeiture of 50,620 shares indicates that the company's stock price did not meet the performance targets set after the Business Combination.
• The failure to meet the stock price targets suggests potential challenges in the company's performance or market perception.

Risks

• The failure to meet stock price targets could negatively impact investor confidence.
• Continued failure to meet performance targets could lead to further forfeitures or other negative consequences for management and employees.

Industry Context

This type of share forfeiture is not uncommon when companies set performance-based vesting conditions for equity grants, particularly after mergers or acquisitions. It highlights the importance of achieving specific financial or operational targets to realize the full value of equity compensation.

Comparison to Industry Standards

• Many companies use stock price targets as part of their executive compensation plans, particularly in the biotech and healthcare sectors.
• The specific targets of $12.50 and $15.00 per share are unique to Oncology Institute's agreement, but the concept of forfeiting shares for not meeting targets is a standard practice.
• Companies like Amgen, Gilead, and Regeneron also use performance-based equity grants, but the specific metrics and targets vary widely based on company-specific goals and market conditions.

Stakeholder Impact

• Shareholders may view the missed targets and share forfeitures negatively.
• Employees may be concerned about the company's performance and future compensation.

Key Dates

Keywords

Oncology Institute, stock forfeiture, earn-out targets, restricted shares, director, performance targets, stock price, business combination